<DOC>
	<DOC>NCT01168310</DOC>
	<brief_summary>This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.</brief_summary>
	<brief_title>A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Able to understand the requirements of the study and provide written informed consent A clinical diagnosis of COPD A current or prior history of at least 10pack years of cigarette smoking Women of childbearing potential (WOCBP) must have a negative pregnancy test at the screening visit and agree to avoid becoming pregnant for the duration of study A clinical diagnosis of Asthma Other significant disease than COPD Subjects who radiation or chemotherapy within the previous 12 months Subjects who had any lung resection QTcB greater than 0.460 seconds History of illegal drug abuse or alcohol abuse within the past 5 years</criteria>
	<gender>All</gender>
	<minimum_age>40 Days</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pulmonary, Obstructive, lungs, COPD</keyword>
</DOC>